# Supplementary Material

Supplementary Table 1.Levels of Aβ1-40 (pg/mL) in CSF (mean ± SD; N= 14–19; PP population).

|  |  |  |
| --- | --- | --- |
|  | **PE-treated** | **Control** |
| Baseline | 6226 ± 2121 | 5824 ± 1650 |
| Treatment phase |  |  |
| Week 3 | 6098 ± 2577 | 7191 ± 1678 |
| Week 9 | 5739 ± 2508 | 5786 ± 1930 |
| Week 21 | 6739 ± 2712 | 6241 ± 2101 |
| Follow-up |  |  |
| Week 33 | 5844 ± 2245 | 5754 ± 2326 |
| Week 44 | 6073 ± 2211 | 5746 ± 2408 |

Supplementary Table 2.Levels of Aβ1-42 (pg/mL) in CSF (mean ± SD; N= 14–19; PP population).

|  |  |  |
| --- | --- | --- |
|  | **PE-treated** | **Control** |
| Baseline | 348.6 ± 154.4 | 304.1 ± 121.3 |
| Treatment phase |  |  |
| Week 3 | 384.4 ± 129.4 | 330.8 ± 119.6 |
| Week 9 | 336.5 ± 160.7 | 307.2 ± 150.1 |
| Week 21 | 398.0 ± 273.8 | 256.7 ± 100.5 |
| Follow-up |  |  |
| Week 33 | 317.6 ± 173.2 | 248.6 ± 129.0 |
| Week 44 | 325.9 ± 172.0 | 249.2 ± 154.2 |

Supplementary Table 3.Plasma levels of Aβ1-40 (pg/mL) before and after plasma exchange (PE) (N= 14-19; PP population).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **PE-treated** | | **Control** | |
|  | **Before PE / no PE** | **After PE** | **Before PE / no PE** | **After PE** |
| Baseline | 116.9 ± 54.1 | N/A | 126.7 ± 43.2 | N/A |
| PE 1 | 114.5 ± 58.0 | 233.0 ± 80.6 | 105.8 ± 47.7 | 132.3 ± 55.0 |
| PE 2 | 144.9 ± 58.4 | 272.9 ± 90.4 | 108.1 ± 40.9 | 134.5 ± 42.5 |
| PE 3 | 149.3 ± 71.1 | 276.1 ± 81.9 | 121.3 ± 40.1 | 123.4 ± 42.5 |
| PE 4 | 166.1 ± 49.4 | 260.2 ± 91.3 | 122.8 ± 40.7 | 125.1 ± 60.0 |
| PE 5 | 153.6 ± 50.8 | 255.4 ± 89.4 | 118.0 ± 39.5 | 110.9 ± 57.1 |
| PE 6 | 167.2 ± 69.7 | 255.7 ± 98.4 | 123.3 ± 46.6 | 123.9 ± 53.7 |
| PE 7 | 150.7 ± 51.3 | 285.5 ± 125.2 | 139.7 ± 41.8 | 161.8 ± 42.5 |
| PE 8 | 172.8 ± 44.7 | 273.8 ± 83.2 | 133.7 ± 42.0 | 147.2 ± 42.9 |
| PE 9 | 170.3 ± 58.9 | 261.3 ± 86.5 | 135.5 ± 43.0 | 144.2 ± 52.8 |
| PE 10 | 159.4 ± 52.3 | 267.3 ± 84.8 | 136.7 ± 40.3 | 152.0 ± 35.2 |
| PE 11 | 173.2 ± 47.6 | 283.2 ± 97.1 | 132.4 ± 37.2 | 141.9 ± 37.3 |
| PE 12 | 181.5 ± 48.5 | 287.1 ± 98.6 | 143.7 ± 44.7 | 150.4 ± 54.4 |
| PE 13 | 150.0 ± 66.0 | 262.8 ± 86.6 | 129.6 ± 40.3 | 153.3 ± 44.7 |
| PE 14 | 226.5 ± 220.8 | 266.0 ± 97.8 | 145.6 ± 41.1 | 159.8 ± 54.7 |
| PE 15 | 166.7 ± 61.9 | 273.8 ± 97.5 | 137.6 ± 36.2 | 159.6 ± 58.0 |
| PE 16 | 169.0 ± 58.7 | 259.8 ± 77.7 | 141.1 ± 44.4 | 156.1 ± 47.1 |
| PE 17 | 169.5 ± 66.7 | 243.1 ± 91.5 | 128.4 ± 33.2 | 151.6 ± 67.0 |
| PE 18 | 161.8 ± 70.9 | 245.9 ± 102.0 | 136.6 ± 32.0 | 135.4 ± 50.2 |
| Follow-up | 153.3 ± 50.6 | N/A | 136.9 ± 37.3 | N/A |
| Final | 148.1 ± 42.9 | N/A | 147.1 ± 23.4 | N/A |

N/A, not applicable

Supplementary Table 4.Plasma levels of Aβ1-42 (pg/mL) before and after plasma exchange (PE) (N= 14-19; PP population).

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **PE-treated** | | | **Control** | | |
|  | | **Before PE / no PE** | **After PE** | | **Before PE / no PE** | **After PE** |
| Baseline | | 44.2 ± 81.1 | N/A | | 49.5 ± 43.7 | N/A |
| PE 1 | | 21.7 ± 22.3 | 25.4 ± 22.7 | | 33.4 ± 29.1 | 39.8 ± 31.7 |
| PE 2 | | 24.8 ± 24.1 | 21.4 ± 13.4 | | 42.0 ± 31.6 | 31.6 ± 24.6 |
| PE 3 | | 22.7 ± 21.6 | 20.6 ± 13.9 | | 39.7 ± 28.9 | 33.0 ± 23.2 |
| PE 4 | | 30.7 ± 26.9 | 20.3 ± 14.1 | | 50.9 ± 42.5 | 30.8 ± 18.8 |
| PE 5 | | 22.5 ± 18.9 | 29.1 ± 21.6 | | 36.7 ± 31.2 | 43.6 ± 29.0 |
| PE 6 | | 29.9 ± 23.9 | 29.1 ± 23.2 | | 49.0 ± 39.2 | 45.4 ± 31.3 |
| PE 7 | | 29.5 ± 30.9 | 33.4 ± 27.6 | | 58.5 ± 68.1 | 55.3 ± 56.8 |
| PE 8 | | 33.2 ± 28.4 | 34.9 ± 27.5 | | 53.2 ± 46.3 | 48.3 ± 41.3 |
| PE 9 | | 37.1 ± 33.5 | 30.8 ± 26.4 | | 49.0 ± 37.8 | 45.9 ± 41.0 |
| PE 10 | | 36.4 ± 35.1 | 30.2 ± 28.4 | | 49.4 ± 35.4 | 46.1 ± 48.4 |
| PE 11 | | 40.5 ± 37.1 | 27.4 ± 20.0 | | 55.1 ± 51.3 | 46.0 ± 52.3 |
| PE 12 | | 37.8 ± 42.8 | 25.1 ± 21.0 | | 49.3 ± 50.1 | 41.4 ± 35.5 |
| PE 13 | | 36.4 ± 35.9 | 41.0 ± 41.5 | | 51.2 ± 48.3 | 57.4 ± 56.6 |
| PE 14 | | 35.4 ± 37.2 | 38.2 ± 40.6 | | 48.1 ± 40.0 | 54.5 ± 50.4 |
| PE 15 | | 42.1 ± 45.9 | 39.3 ± 39.2 | | 48.6 ± 42.1 | 48.9 ± 60.5 |
| PE 16 | | 47.1 ± 51.9 | 36.2 ± 36.4 | | 51.0 ± 41.6 | 52.8 ± 69.0 |
| PE 17 | | 49.7 ± 53.9 | 35.9 ± 33.2 | | 52.9 ± 50.1 | 45.2 ± 39.1 |
| PE 18 | | 52.8 ± 68.5 | 37.1 ± 40.9 | | 60.8 ± 61.3 | 45.3 ± 42.4 |
| Follow-up | | 10.1 ± 12.9 | N/A | | 10.2 ± 16.7 | N/A |
| Final | | 10.8 ± 11.7 | N/A | | 11.7 ± 20.8 | N/A |

N/A, Not applicable

Supplementary Figure 1.Levels of Aβ1-40 plotted as the average amount of mobilized peptide per mL of plasma processed and per day (A, rate of change) and the absolute (per mL) peptide mobilization (B) by treatment period (intensive, maintenance I and maintenance II) in plasma exchange (PE)-treated patients and controls (sham PE).

